Trial
NCT02457910
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
National Cancer Institute (NCI); Translational Breast Cancer Research Consortium; Conquer Cancer Foundation; Genentech, Inc.
Condition
Estrogen Receptor Negative
Intervention
Biomarker Analysis
Why stopped
Interim analysis - toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-22